It looks to be a relatively quiet American Society of Clinical Oncology (ASCO) meeting this year, judging by Wall Street's sedate reaction to Wednesday evening's abstract dump, an event that usually sends stocks jumping while analysts and investors scramble to keep up. Read More
Aesthetic specialist Kythera Biopharmaceuticals Inc. filed an S-1 with the SEC seeking to raise $86.2 million in an initial public offering, with "substantially all" of the net proceeds used to fund U.S. Phase III trials of lead compound ATX-101, according to the filing. Read More
Anti-anxiety drugs such as the benzodiazepines target receptors for the neurotransmitter GABA, which is the main inhibitory neurotransmitter of the brain. Read More
Sosei Group Corp. reported that NVA237 beat placebo at improving lung function, symptom relief and quality of life among sufferers of chronic obstructive pulmonary disease (COPD) in its Phase III GLOW2 trial. Read More
• Agilent Technologies Inc., of Santa Clara, Calif., will acquire Dako Denmark A/S, a cancer diagnostic company based in Glostrup, Denmark, for $2.2 billion, the largest acquisition in Agilent's history. Agilent seeks to boost its revenue and presence in life sciences. Dako produces antibodies, reagents, instruments and software for the cancer diagnostic market, and collaborates with major pharmaceutical companies to develop new companion diagnostic products. Read More
• Esperance Pharmaceuticals Inc., of Baton Rouge, La., began enrolling patients in a randomized, multicenter Phase II trial of EP-100 plus paclitaxel in advanced ovarian cancer. EP-100 is a targeted membrane-disrupting peptide (tMDP) designed to seek and destroy cancer cells that overexpress luteinizing hormone-releasing hormone receptors on their surfaces. Read More
• Pfizer Canada Inc., of Kirkland, Quebec, part of Pfizer Inc., launched Xyntha Solofuse in Canada to prevent and control hemorrhagic episodes in patients with hemophilia A. Read More
